LiDCO Group Plc
30 March 2005


For immediate release                                              30 March 2005


                                LiDCO GROUP PLC
                                   ("LiDCO")

            Lithium Chloride Mutual Recognition Approval in Denmark

LiDCO Group plc, (AIM: LID) the UK-based cardiovascular monitoring company, is
pleased to announce today that a further European approval of Lithium Chloride
for use with the LiDCOplus System has been granted in Denmark.  Lithium Chloride
is used in conjunction with the LiDCOplus System to provide an absolute measure
of a patients cardiac output.

This latest registration now provides LiDCO with full marketing approval in a
portfolio of thirteen European countries including UK, Spain, Germany, Austria,
Italy, Czech Republic, Belgium and Holland, Ireland, Norway, Sweden, Bulgaria
and Denmark.

Commenting on the approval in Denmark, Dr Terry O'Brien, LiDCO's CEO, said:
"Following on from the recent approvals in Ireland, Norway, Sweden and Bulgaria
we have now registered the lithium chloride injection as a pharmaceutical
(in-vivo diagnostic) in a further European market. Europe is the most developed
territory for the adoption of advanced minimally invasive cardiovascular
monitoring and with this extended group of territories we expect the growth in
European sales to be further accelerated in 2005."


For further information please contact:

LiDCO Group Plc
Terry O'Brien (CEO) terry@lidco.com                              020 7749 1500

Buchanan Communications
Tim Anderson, Mary-Jane Johnson, James Strong                    020 7466 5000

Notes for Editors

LiDCO is a leading developer of minimally invasive, computer-based hemodynamic
monitoring equipment and disposables used primarily for the management of
critical care and cardiovascular risk hospital patients. The Company's current
products are:

  • the LiDCOplus and PulseCO monitors, computer-based platforms for
    displaying a range of real-time continuous hemodynamic parameters including
    cardiac output, oxygen delivery and fluid volume; and
  • the LiDCO disposable for accurately determining cardiac output in a
    minimally-invasive manner.

Lithium dilution calibrated waveform analysis

The LiDCOplus monitor uses arterial pressure waveform analysis, in conjunction
with Lithium dilution cardiac output calibration.  Lithium does not occur
naturally in the body. Making this a patentable reference indicator.  The
injected lithium is used in trace amounts as an in vivo diagnostic, not a
therapeutic drug, to calibrate the PulseCO continuous beat to beat software.
The measurement of the marker lithium ion concentration in blood is made through
a proprietary lithium selected ion sensor attached to existing radial or other
peripheral arterial lines.  The lithium is injected into the venous circulation
via a central venous or peripheral venous line.  The lithium cardiac output
determination is then used to calibrate cardiac output continuously from the
arterial pulse power profile of the pressure waveform.


                      This information is provided by RNS
            The company news service from the London Stock Exchange